Hepatitis C drug development at a crossroads

Hepatology

Volumn 50, Issue 4, 2009, Pages 997-999

  Nelson, David R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; ITMN 191; PEGINTERFERON; PROTEINASE INHIBITOR; R 7128; RIBAVIRIN; TELAPREVIR; ALPHA2A INTERFERON; DRUG DERIVATIVE; MACROGOL DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; PROLINE;

ANEMIA; CARDIOMYOPATHY; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDITORIAL; GENE MUTATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RELAPSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE; DRUG COMBINATION; ENZYMOLOGY; HEPATITIS C VIRUS; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 70350061698     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23208     Document Type: Editorial

References (14)

1. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
2. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.
3. Kwo P, Lawitz E, Malone J, Schiff E, Vierling J, Pound D, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron/ribavirin in treatment naïve subjects with genotype-1 chronic hepatitis C. J Hepatol 2009, 1(50):54.
4. Manns M, Muir A, Adda N, Jacobsen I, Afdhal N, Heathcote J, et al. Telaprevir in hepatitis C genotype-1-infected patients with prior nonresponse, viral breakthrough or relapse to peginterferon-alfa2a/b and ribavirin therapy: SVR results of the PROVE3 study. Program and abstracts of the 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen, Denmark [Abstract 1044].
5. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007;47:631-639.
6. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. HEPATOLOGY 2008;48:1769-1778.
7. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of U.S. Veterans to treatment for the hepatitis C virus. HEPATOLOGY 2007; 46:37-47.
8. Grunberger C, Wyles DL, Kaihara KA, Schooley RT. 3-Drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis 2008;197:42.
9. Olsen D, et al. A combination of direct antiviral compounds show synergistic activity in vitro and enhanced efficacy in vivo. In program and abstracts of the 18th Conference of the Asian Pacific Association for the Study of Liver, Seoul, Korea, March 23-26, 2008 [Abstract] [FP149].
10. Gane EJ, Roberts C, Stedman C, Angus PW, Ritchie B, Elston R. Firstin-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virology results from INFORM-1. J Hepatol 2009;50:S380.
11. Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D, et al. Development of novel agents for the treatment of chronic hepatitis C infection: summary of the FDA Antiviral Products Advisory Committee recommendations. HEPATOLOGY 2007;46:2014-2020.
12. DiBisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441.
13. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007;45:579-587.
14. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hoffmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684.